These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27285457)

  • 1. PROTECTIVE EFFECTS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON PROGRESSION OF DIABETIC RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES.
    Chung YR; Park SW; Kim JW; Kim JH; Lee K
    Retina; 2016 Dec; 36(12):2357-2363. PubMed ID: 27285457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy.
    Cho EH; Park SJ; Han S; Song JH; Lee K; Chung YR
    J Diabetes Res; 2018; 2018():6807219. PubMed ID: 30622970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease.
    Jeong SH; Chung SJ; Yoo HS; Hong N; Jung JH; Baik K; Lee YH; Sohn YH; Lee PH
    Brain; 2021 May; 144(4):1127-1137. PubMed ID: 33895825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating dipeptidyl peptidase-4 activity is associated with diabetic retinopathy in type 1 diabetic patients.
    Blaslov K; Bulum T; Duvnjak L
    Eur J Ophthalmol; 2015; 25(4):328-32. PubMed ID: 25588592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study.
    Kim NH; Choi J; Kim NH; Choi KM; Baik SH; Lee J; Kim SG
    Diabetes Metab; 2018 Sep; 44(4):361-367. PubMed ID: 29752167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study.
    Chung YR; Ha KH; Lee K; Kim DJ
    PLoS One; 2019; 14(10):e0224549. PubMed ID: 31658289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.
    Patil HR; Al Badarin FJ; Al Shami HA; Bhatti SK; Lavie CJ; Bell DS; O'Keefe JH
    Am J Cardiol; 2012 Sep; 110(6):826-33. PubMed ID: 22703861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture.
    Driessen JH; van Onzenoort HA; Henry RM; Lalmohamed A; van den Bergh JP; Neef C; Leufkens HG; de Vries F
    Bone; 2014 Nov; 68():124-30. PubMed ID: 25093264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dipeptidyl peptidase-4 inhibitor in patients undergoing bypass surgery.
    Ogawa S; Okawa Y; Sawada K; Goto Y; Fukaya S; Suzuki T
    Asian Cardiovasc Thorac Ann; 2016 Nov; 24(9):863-867. PubMed ID: 27784818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.
    Detournay B; Halimi S; Robert J; Deschaseaux C; Dejager S
    Vasc Health Risk Manag; 2015; 11():417-25. PubMed ID: 26229480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First Incidence and Progression Study for Diabetic Retinopathy in Portugal, the RETINODIAB Study: Evaluation of the Screening Program for Lisbon Region.
    Dutra Medeiros M; Mesquita E; Gardete-Correia L; Moita J; Genro V; Papoila AL; Amaral-Turkman A; Raposo JF
    Ophthalmology; 2015 Dec; 122(12):2473-81. PubMed ID: 26383994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase-4 inhibitors are associated with improved left ventricular diastolic function after acute myocardial infarction in diabetic patients.
    Fujiwara T; Yoshida M; Nakamura T; Sakakura K; Wada H; Arao K; Katayama T; Funayama H; Sugawara Y; Mitsuhashi T; Kakei M; Momomura S; Ako J
    Heart Vessels; 2015 Sep; 30(5):696-701. PubMed ID: 24736945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy.
    Dietrich N; Kolibabka M; Busch S; Bugert P; Kaiser U; Lin J; Fleming T; Morcos M; Klein T; Schlotterer A; Hammes HP
    PLoS One; 2016; 11(12):e0167853. PubMed ID: 27942008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diabetes self-management and its association with diabetic retinopathy in patients with type 2 diabetes].
    Li N; Yang XF; Deng Y; Gu H; Ren XT; Xu J; Ma K; Liu NP
    Zhonghua Yan Ke Za Zhi; 2013 Jun; 49(6):500-6. PubMed ID: 24119962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs.
    Driessen JH; van Onzenoort HA; Starup-Linde J; Henry R; Neef C; van den Bergh J; Vestergaard P; de Vries F; Burden AM
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1017-25. PubMed ID: 26183226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Sjølie AK; Klein R; Porta M; Orchard T; Fuller J; Parving HH; Bilous R; Aldington S; Chaturvedi N
    Diabet Med; 2011 Mar; 28(3):345-51. PubMed ID: 21309844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and progression of diabetic retinopathy in Hong Kong Chinese with type 2 diabetes mellitus.
    Tam VH; Lam EP; Chu BC; Tse KK; Fung LM
    J Diabetes Complications; 2009; 23(3):185-93. PubMed ID: 18479945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitors and bone metabolism: is vitamin D the link?
    Barchetta I; Cimini FA; Bloise D; Cavallo MG
    Acta Diabetol; 2016 Oct; 53(5):839-44. PubMed ID: 27379733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in patients with severe nonproliferative or non-high-risk proliferative diabetic retinopathy: a randomized clinical trial.
    Scott IU; Jackson GR; Quillen DA; Larsen M; Klein R; Liao J; Holfort S; Munch IC; Gardner TW
    JAMA Ophthalmol; 2014 May; 132(5):535-43. PubMed ID: 24604308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The protective role of DPP4 inhibitors in atherosclerosis.
    Liu H; Guo L; Xing J; Li P; Sang H; Hu X; Du Y; Zhao L; Song R; Gu H
    Eur J Pharmacol; 2020 May; 875():173037. PubMed ID: 32097656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.